Marshall Wace, LLP Acumen Pharmaceuticals, Inc. Transaction History

Marshall Wace, LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.97 - $4.64 $266,429 - $416,240	89,707 New	89,707 $363,000
Q3 2023 Nov 14, 2023	BUY	$4.15 - $9.72 $105,791 - $247,782	25,492 New	25,492 $105,000
Q2 2022 Aug 15, 2022	SELL	$3.08 - $4.88 $43,172 - $68,402	-14,017 Reduced 42.7%	18,808 $89,000
Q1 2022 May 16, 2022	SELL	$3.91 - $6.73 $482,591 - $830,650	-123,425 Reduced 78.99%	32,825 $129,000
Q3 2021 Nov 15, 2021	BUY	$14.5 - $20.28 $2.27 Million - $3.17 Million	156,250 New	156,250 $2.32 Million

41.8M

57.7K

749K

Ticker ABOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,503,100
Market Cap $79.8M
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.